

## CURRICULUM VITAE

**CHARLES S. WILCOX, Ph.D., M.P.A., M.B.A.****Praxis Research Consulting**

Work Address:

5031 Birch Street  
Suite 110  
Newport Beach, CA 92660  
(949) 877-6103

EDUCATION

- 1978 B.S. University of Southern California  
Public Affairs/Administration, With Honors
- 1979 M.P.A. University of Southern California  
Emphasis in Systems Analysis and  
Manpower Management/Personnel Administration
- 1982 M.B.A. University of Southern California  
Emphasis in Marketing, Marketing Research and  
Consulting Services (Certification/Completion in 1992)
- 1989 Ph.D. University of Southern California  
Four areas of specialization/qualification:  
1) Applied Behavioral Sciences, 2) Research,  
3) Administrative Theory, 4) Organizational Behavior  
Dissertation: Questions of and by Questionnaires...

EXPERIENCE

- 2019-Present Praxis Research Consulting  
Newport Beach, California  
Chief Executive Officer
- Currently serving on Board(s) of Directors for both private (i.e., for profit) and public (i.e., non-profit 501c3) organizations, including scientific advisory boards. Consultative roles encompass a wide array of clinical research, marketing research and personnel management. Clients have included public and private corporations, as well as universities and V.A. hospitals.
- 1984-2019 Pharmacology Research Institute  
Los Alamitos/Newport Beach/Encino, California  
Executive Director/Owner/Founder

Responsibilities include the solicitation and negotiation of all grant funding for the Institute. In addition to the overall conduct (and sometimes design) of clinical investigations, operational duties include: planning, staffing, budgeting, patient recruitment, fulfillment of and compliance with U.S. and foreign regulatory requirements as well as the dissemination (i.e., publication and presentation) of results. Clinical responsibilities include preliminary pre-screening of patients, global ratings (i.e., A.D.A.S.-Cog C.G.I.C., C.D.R. and C.I.B.I.C.-Plus, etc.), medication accountability and assistance with informed consent processes.

1981-1984

Psychopharmacology Research Associates, Inc.  
Executive Director

Co-founder of this California non-profit (501 c 3) corporation. Directly responsible for the procurement of grants, gifts, and donations. Administrative duties included technical and professional staffing as well as the establishment and maintenance of collaborative relationships with public and private institutions.

1979-1981

Psychopharmacology Unit  
University of California, Irvine (affiliate)  
Administrative Analyst

Primary responsibilities included the logistical planning, staffing, and budgeting of clinical research investigations. Also responsible for the organization's compliance with updated/revised rules and guidelines set forth by the Food and Drug Administration (FDA). Additional tasks included representation of the research unit at both governmental and corporate audits.

1978-1979

Psychopharmacology Research Unit  
University of California, Irvine (affiliate)  
Research Administrator

Responsible for the quality and timely conduct of clinical investigations of new chemical entities; majority of duties related to the quality of data collection forms prior to submission of the data to sponsors/FDA. Advised in the recruitment and selection of administrative and clerical personnel.

1978

State of California, Governor's Office,  
Office of Planning and Research,  
Sacramento, California  
Assistant Policy Analyst

Assistant (part-time) to Dr. Carl Werthman at U.S.C., performed analytical studies on proposed government policies; reported criticisms and recommendations for future state planning and reference.

1977

The American Petroleum Institute  
Washington, D.C.  
Legislative Analyst

Initially a traditional/part-time internship, responsibilities included attendance at and the reporting of United States Senate and House Committee meeting proceedings for dissemination to sponsors and affiliates of the Institute. Duties ultimately expanded to include the briefing of industry representatives in preparation for Congressional Committee testimony.

- 1976                      Joint Educational Project  
University of Southern California  
Spanish/English Tutor
- Responsibilities included developing and implementing teaching methodologies to assist Spanish-speaking students in acquiring fundamental English verbal skills.

CONSULTANCIES (Partial)

- 2020-Present            Syneos Health Site Advocacy Group (SAG) for Protocol Optimization  
Society for Clinical Research Sites (SCRS)
- 2016-2019                Alzheimer’s Orange County Medical and Scientific Advisory Board
- 2015-2019                INC Research Site Advocacy Group (SAG) for Protocol Optimization  
Society for Clinical Research Sites (SCRS)

RELATED VOLUNTEER WORK

Alzheimer’s Association, Orange County Chapter  
Board of Directors

Alzheimer's Los Angeles Speakers Bureau  
4221 Wilshire Blvd. Suite 400  
Los Angeles, California 90010

and  
Alzheimer’s Orange County Speakers Bureau  
2515 Mc Cabe Way, #200  
Irvine, California 92614

The STARR Coalition Diversity Workgroup

AIM: Alzheimer’s Impact Movement – Leadership and Advocacy Council

ORGANIZATIONS

American Headache Society  
Drug Information Association  
Society for Clinical Research Sites

Pi Alpha Alpha National Honor Society  
Regulatory Affairs Professionals Society  
American Federation of Medical Research  
Society for Research on Nicotine and Tobacco  
European College of Neuropsychopharmacology  
American Society of Clinical Psychopharmacology  
American Society of Public Administration (Life Member)  
International Society for CNS Clinical Trials and Methodology  
American Professional Society of ADHD and Related Disorders  
International Society to Advance Alzheimer's Research and Treatment  
Association of Clinical Research Professionals (C.C.R.C. Certified 1992)

## PUBLICATIONS

1. Cohn, J.B. and Wilcox, C.S. Dangerousness as a standard for civil commitment. *American Journal of Forensic Psychiatry* 1(4): 169-174, 1983.
2. Cohn, J.B. and Wilcox, C.S. Long-term comparison of alprazolam, lorazepam and placebo in patients with an anxiety disorder. *Pharmacotherapy* 4(2): 93-98, 1984.
3. Cohn, J.B.; Wilcox, C.S. and Cohn, J. Treatment of the anxious elderly patient. *Geriatric Medicine Today* 3(12): 45-55, 1984.
4. Cohn, J.B. and Wilcox, C.S. Comparison of fluoxetine, imipramine and placebo in patients with major depressive disorder. *Journal of Clinical Psychiatry* 46(3): 26-31, 1985.
5. Cohn, J.B. and Wilcox, C.S. Praxilene in the treatment of senile dementia. In: *Conservative Therapy of Arterial Occlusive Disease*, G. Trubestein (ed.), Georg Thieme Verlag Stuttgart, New York, 1986, pp. 330-333.
6. Cohn, J.B.; Wilcox, C.S. and Meltzer, H.Y. Neuroendocrine effects of buspirone in patients with generalized anxiety disorder. *American Journal of Medicine* 80 (suppl. 3B): 36-40, March 1986.
7. Cohn, J.B. and Wilcox, C.S. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study. *Journal of Clinical Psychiatry* 47(8): 409-412, August 1986.
8. Cohn, J.B. and Wilcox, C.S. Buspirone: effectiveness, safety and mechanisms of action. *IM-Internal Medicine for the Specialist* 8(1): 216-224, January 1987.
9. Cohn, J.B. and Wilcox, C.S. Diagnostic criteria for Alzheimer's disease: an evaluation. *Geriatric Medicine Today* 6(61): 77-88, June 1987.
10. Cohn, J.B.; Pyke, R.E. and Wilcox, C.S. Adinazolam mesylate and placebo in depressed outpatients: a 6-week double-blind comparison. *Journal of Clinical Psychiatry* 49(4): 142-147, 1988.

11. Cohn, J.B.; Pyke, R.E. and Wilcox, C.S. Adinazolam mesylate and placebo in depressed outpatients. *Psychiatry Digest*, pp. 13-14, December 1988.
12. Cohn, J.B. and Wilcox, C.S. Baixo Potencial de Sedacao da Buspirona Comparado com Alprazolam e Lorazepam no Tratamento de Pacientes com Ansiedade: Um Estado Duplo-Cego. *Revista Brasileira de Medicina* Vol. 46, Nos. 1/2, Jan/Feb, 1989.
13. Crowder, J.E.; Cohn, J.B.; Savitsky, J.P.; Morgan, D.L.; Slywka, J.; Cobert, B.L.; Hryniewicki, S.W.; Piccirillo, R.T.; and Wilcox, C.S. Efficacy and safety of pentoxifylline in geriatric patients with intermittent claudication. *Angiology: the Journal of Vascular Diseases* 40(9): 795-802, September 1989.
14. Wilcox, C.S.; Cohn, J.B.; Crowder, J.E. and Ryan, P.J. Patient Motivation and Placebo Response. *Journal of Clinical Research and Pharmacoepidemiology* 4(2): 154, June 1990.
15. Cohn, J.B.; Crowder, J.E.; Wilcox, C.S. and Ryan, P.J. A placebo- and imipramine-controlled study of paroxetine. *Psychopharmacology Bulletin* 26(2): 185-189, 1990.
16. Cohn, J.B.; Wilcox, C.S.; Bremner, J. and Ettinger, M. Hypnotic efficacy of estazolam compared with flurazepam in outpatients with insomnia. *Journal of Clinical Pharmacology* 31(8): 747-750, August 1991.
17. Cohn, J.B.; Wilcox, C.S. and Lerer, B.E. Development of an 'Early' Detection Battery for Dementia of the Alzheimer Type. *Progress in Neuro-psychopharmacology & Biological Psychiatry* 15: 433-479, 1991.
18. Cohn, J.B.; Wilcox, C.S.; Bowden, C.L.; Fisher, J.G. and Rodos, J.J. Double-blind comparison of buspirona and clorazepate in anxious outpatients with and without depressive symptoms. *Psychopathology* 25(S1): 10-21, 1992.
19. Cohn, J.B. and Wilcox, C.S. Paroxetine in Major Depression: A double-blind trial with imipramine and placebo. *Journal of Clinical Psychiatry* 53:2(suppl): 52-56, February 1992.
20. Wilcox, C.S.; Cohn, J.B.; Linden, R.D.; Heiser, J.F.; Lucas, P.B.; Morgan, D.L. and DeFrancisco, D. Predictors of Placebo Response: A retrospective analysis. *Psychopharmacology Bulletin* 28(2): 157-162, 1992.
21. Cohn, J.B.; Wilcox, C.S. and Morrissey, J.L. Differentiating Delirium from Dementia. *American Journal of Forensic Psychiatry* 13(4): 3-25, 1992.
22. Gammans, R.E.; Stringfellow, J.C.; Hvizdos, A.J.; Seidehamel, R.J.; Cohn, J.B.; Wilcox, C.S.; Fabre, L.F.; Pecknold, J.C.; Smith, W.T. and Rickels, K. Use of Buspirona in Patients with Generalized Anxiety Disorder and Coexisting Depressive Symptoms: A Meta-Analysis of Eight Randomized, Controlled Studies. *Neuropsychobiology* 25: 193-201, 1992.

23. Cohn, J.B.; Wilcox, C.S. and Goodman, L.I. Antidepressant Efficacy and Cardiac Safety of Trimipramine in Patients with Mild Heart Disease. *Clinical Therapeutics* 15 (No.1): 114-126, 1993.
24. Wilcox, C.S.; Ryan, P.J.; Morrissey, J.L.; Cohn, J.B.; De Francisco, D.F.; Linden, R.D. and Heiser, J.F. A Fixed-Dose Study of Adinazolam-SR Tablets in Generalized Anxiety Disorder. *Prog. Neuro-Psychopharmacol. & Biol. Psychiat* 18: 979-993, 1994.
25. Linden, R.D.; Wilcox, C.S.; Heiser, J.F.; Cavanaugh, E. and Wisselink, P.G. Are Selective Serotonin Re-uptake Inhibitors Well Tolerated in Somatizing Depressives? *Psychopharmacology Bulletin*, 30(2): 151-156, 1994.
26. Heiser, J.F. and Wilcox, C.S. "Book Review" Human Psychopharmacology—Measures and Methods, Volume 4, I. Hindmarch and P.D. Stonier (editors), *The Annals of Pharmacotherapy* 28: 1205, October 1994.
27. Wilcox, C.S.; Cohn, J.B.; Katz, B.B.; Mijares, C.P.; Guarino, J.J.; Panagides, J. and DeFrancisco, D. A Double-Blind, Placebo-Controlled Study Comparing Mianserin and Amitriptyline in Moderately Depressed Outpatients. *International Clinical Psychopharmacology* 9: 271-279, Winter 1994.
28. Wilcox, C.S.; Heiser, J.F.; Crowder, A.M.; Wassom, N.J.; Katz, B.B. and Dale, J.L. Comparison of the Effects on Pupil Size and Accommodation of Three Regimens of Topical Dapiprazole. *British Journal of Ophthalmology* 79(6): 544-548, June 1995.
29. Adams, J.B.; Pyke, R.E.; Costa, J.; Cutler, N.R.; Schweizer, E.; Wilcox, C.S.; Wisselink, P.G.; Greiner, M; Pierce, M.W. and Pande, A.C. A Double-blind, Placebo-Controlled Study of a CCK-B Receptor Antagonist, CI-988, In Patients with Generalized Anxiety Disorder. *The Journal of Clinical Psychopharmacology* 15(6): 428-434, December 1995.
30. Feiger, A.; Kiev, A.; Shrivastava, R.K.; Wisselink, P.G. and Wilcox, C.S. Nefazodone Versus Sertraline in Outpatients with Major Depression: Focus on Efficacy, Tolerability, and Effects on Sexual Function and Satisfaction. *Journal of Clinical Psychiatry* (57): January 1996.
31. Wilcox, C.S.; Katz, B.B.; Morgan, D.L.; Morrissey, J.L.; Schneider, A.L. and DeFrancisco, D.F. Increasing Ethnic Diversity and Managed Care: How Will They Influence Research Patient Recruitment in the 1990s? *Psychopharmacology Bulletin* 32(2): 193-200, 1996.
32. Walczak, D.D.; Apter, J.T.; Halikas, J.A.; Borison, R.L.; Carman, J.S.; Post, G.L.; Patrick, R.; Cohn, J.B.; Cunningham, L.A.; Rittberg, B.; Preskorn, S.H.; Kang, J.S. and Wilcox, C.S. The Oral Dose-Effect Relationship for Fluvoxamine: A Fixed-Dose Comparison Against Placebo in Depressed Outpatients. *Annals of Clinical Psychiatry* 8(3): 139-151, September 1996.
33. Wilcox, C.S.; Ferguson, J.M.; Dale, J.L. and Heiser, J.F. A Double-Blind Trial of a Low Dose Range and High Dose Range of Gepirone-ER Compared to Placebo in the Treatment of Depressed Outpatients. *Psychopharmacology Bulletin* 32(3): 335-342, 1996.

34. Lahmeyer, H.; Wilcox, C.; Kann, J. and Leppik, I. Subjective Efficacy of Zolpidem in Outpatients with Chronic Insomnia. *Clinical Drug Investigation* 12(3): 134-144, March 1997.
35. Schneider, A.L. and Wilcox, C.S. Combined Therapies in the Treatment of Rapid Cycling Lithium Resistant Mania in Geriatric Patients. *Journal of Affective Disorders* 47: 201-205, 1998.
36. Heiser, J.F. and Wilcox, C.S. 5HT<sub>1A</sub> Receptor Agonists as Antidepressants: Pharmacological Rationale and Evidence for Efficacy. *CNS Drugs* 10(5): 343-353, November 1998.
37. Feiger, A.D.; Bielski, R.J.; Bremner, J.; Heiser, J.F.; Trivedi, M.; Wilcox, C.S.; Roberts D.L.; Kensler, T.T.; McQuade, R.D.; Kaplita, S.B. and Archibald, D.G. Double-Blind, Placebo-Substitution Study of Nefazodone in the Prevention of Relapse During Continuation Treatment of Outpatients with Major Depression. *International Clinical Psychopharmacology* 1999, 14: 19-28.
38. Grosz, D.E.; Morrissey, J.L. and Wilcox, C.S. Comparative Effectiveness of Triptans for the Treatment of Migraine. *Today's Therapeutic Trends* 20(2): 97-112, 2002.
39. Wilcox, C.S.; Linden, R.D.; D'Amico, M.F.; DeFrancisco, D.F.; Morrissey, J.L. and Heiser, J.F. Nefazodone in the Treatment of Elderly Patients with Depression. *Today's Therapeutic Trends* 20(2): 183-196, 2002.
40. Thase, M.E.; Ferguson, J.M.; Lydiard, R.B. and Wilcox, C.S. Citalopram Treatment of Paroxetine-Intolerant Depressed Patients. *Depression and Anxiety* 16: 128-133, 2002.
41. Oskooilar, N.; Wilcox, C.S.; Tong, M. and Grosz, D.E. Body Mass Index and Response to Antidepressants in Depressed Research Subjects. *Journal of Clinical Psychiatry* 70:11, 1609-1610, November 2009.
42. Wilcox, C.S.; Oskooilar, N.; Erickson, J.S.; Billes, S.K.; Katz, B.B.; Tollefson, G. and Dunayevich, E. An Open-Label Study of Naltrexone and Bupropion Combination Therapy for Smoking Cessation in Overweight and Obese Subjects. *Addictive Behaviors* 25: 229-234, 2010.
43. Wilcox, C.S.; Noble E.P. and Oskooilar, N. ANKK1/DRD2 Locus Variants Are Associated With Rimonabant Efficacy in Aiding Smoking Cessation: Pilot Data. *Journal of Investigative Medicine* 59(8) 1280-1283, December 2011.
44. Shiovitz, T.M.; Wilcox, C.S.; Gevorgyan, L. and Shawkat, A. CNS Sites Cooperate to Detect Duplicate Subjects with a Clinical Trial Subject Registry. *Innovations in Clinical Neuroscience* 10(2); 17-21, February 2013.
45. Wilcox, C.S.; Franceschi, L. and Simmons, A. Layperson/Plain Language Summaries: Can Sponsors, CROs, and Sites Deliver in 2020? *Innovations in Clinical Neuroscience* 2020;17(7-9) 9-13.

46. Wilcox, C.S. "Supreme Change" is Needed, *PA Times*, American Society for Public Administration. PATIMES.ORG, October 22, 2020.
47. Wilcox, C.S. Diversity, Equity and Inclusion: Alzheimer's and Dementia Research-Related Global Challenges, Solutions and Opportunities, *Innovations in Clinical Neuroscience*, Fall [October-December 2021] Vol. 18, No. 10-11, Supplement 1, pg. S-11.
48. Wilcox, C.S. Alzheimer's #115: A global 3-D perspective for patients, caregivers, clinical researchers, clinicians and concerned citizens, *European Neuropsychopharmacology*, Volume 53, Supplement 1, December 2021, Page S672.

#### ABSTRACTS/VIDEOS & ORAL PRESENTATIONS

1. Cohn, J.B. and Wilcox, C.S. "Effect of withdrawing treatment after long-term administration of alprazolam, lorazepam, or placebo in patients with anxiety disorder," American College of Neuropsychopharmacology, 21<sup>st</sup> Annual Meeting, San Juan, Puerto Rico, December 15-17, 1982.
2. Cohn, J.B. and Wilcox, C.S. "Praxilene in the Treatment of Senile Dementia," International Symposium on Conservative Therapy of Arterial Occlusive Disease, Bonn, Germany, May 25, 1984.
3. Cohn, J.B. and Wilcox, C.S. "Comparison of fluoxetine, imipramine and placebo in patients with major depressive disorder," Collegium Internationale Neuro-Psychopharmacologicum 14th C.I.N.P. Congress, Florence, Italy, July 19-23, 1984.
4. Cohn, J.B.; Feigenbaum, A.S. and Wilcox, C.S. "An investigation of ORG 2766 in primary degenerative dementia," II International Congress on Psychogeriatric Medicine, Umeå, Sweden, August 30, 1985.
5. Cohn, J.B.; Feigenbaum, A.S. and Wilcox, C.S. "Treatment of Alzheimer's disease with oral analogue of ACTH," IV World Congress of Psychiatry, Philadelphia, Pennsylvania, September 9, 1985.
6. Cohn, J.B. and Wilcox, C.S. "Evaluation of Alzheimer's disease diagnostic criteria," Collegium Internationale Neuro-Psychopharmacologicum, 15<sup>th</sup> C.I.N.P. Congress, Puerto Rico, December 16- 20, 1986.
7. Wilcox, C.S.; Hamilton, M.; Cohn, J.B. and Addis, B. The Hamilton Depression Rating Scale: A training film for the assessment of depressed patients. University of California at Los Angeles, Behavioral Sciences Media Laboratory, April 14, 1987.
8. Wilcox, C.S.; Hamilton, M.; Cohn, J.B. and Addis, B. The Hamilton Anxiety Rating Scale: A training film for the assessment of anxious patients. University of California at Los Angeles, Behavioral Sciences Media Laboratory, April 15, 1987.



9. Wilcox, C.S.; Cohn, J.B. and Pyke, R.E. "A six-week, double-blind comparison of adinazolam mesylate and placebo in depressed outpatients," X<sup>th</sup> International Congress of Pharmacology, Sydney, Australia, August 27, 1987.
10. Cohn, J.B.; Crowder, J.E.; Wilcox, C.S. and Ryan, P.J. "A placebo- and imipramine-controlled study of paroxetine," 29<sup>th</sup> Annual NCDEU Meeting, Key Biscayne, Florida, June 2, 1989.
11. Cohn, J.B.; Wilcox, C.S. and Lerer, B.E. "Development of an Early Detection Battery for Dementia of the Alzheimer's Type," American College of Neuropsychopharmacology, Maui, Hawaii, December 11, 1989.
12. Wilcox, C.S.; Cohn, J.B.; Crowder, J.E. and Ryan, P.J. "Patient Motivation and Placebo Response," Associates of Clinical Pharmacology, Annual Meeting, Montreal, Quebec, Canada, May 9, 1990.
13. Cohn, J.B. and Wilcox, C.S. "From Delirium to Dementia," 17<sup>th</sup> Collegium Internationale Neuro-Psychopharmacologicum, Kyoto, Japan, September 14, 1990.
14. Cohn, J.B.; Wilcox, C.S.; Crowder, J.E.; Guarino, J.J. and Ryan, P.J. "A Controlled Study of Mianserin in Moderately to Severely Depressed Outpatients," American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 10, 1990.
15. Wilcox, C.S.; Cohn, J.B.; Linden, R.D.; Heiser, J.F. and Lucas, P.B. "Predictors of Placebo Response: A Retrospective Analysis," 31<sup>st</sup> Annual NCDEU Meeting, Key Biscayne, Florida, May 30, 1991.
16. Wilcox, C.S.; Ryan, P.J.; Cohn, J.B.; Morrissey, J.M.; Linden, R.D. and Heiser, J.F. "A Fixed-Dose Study of Adinazolam-SR Tablets in Generalized Anxiety Disorder: A Preliminary Report," 30<sup>th</sup> Annual A.C.N.P. Meeting, San Juan, Puerto Rico, December 9-12, 1991.
17. Wilcox, C.S.; Cohn, J.B.; Katz, B.B.; Mijares, C.P.; DeFrancisco, D.; Heiser, J.F. and Linden, R.D. "A Placebo-Controlled Study of Two Arylpiperazines in Outpatients with Generalized Anxiety Disorder (GAD)," 31<sup>st</sup> Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 15, 1992.
18. Wilcox, C.S. "Drug Development in the 1990s: Bringing New Drugs to Market in the United States," California State University, Los Angeles, CME Guest Speaker, Los Angeles, California, May 5, 1993.
19. Linden, R.D.; Wilcox, C.S.; Heiser, J.F.; Cavanaugh, E.; and Wisselink, P.G. "Are S.S.R.I.s Well Tolerated in Somatizing Depressives?" 33<sup>rd</sup> Annual NCDEU Meeting, Boca Raton, Florida, June 2, 1993.

20. Wilcox, C.S.; Heiser, J.F.; Cohn, J.B.; Dale, J.L.; Linden, R.D.; Katz, B.B.; Morrissey, J.L. and DeFrancisco, D.F. "Placebo Response in G.A.D. Trials: An Analysis of Purported Predictors," 32<sup>nd</sup> Annual Meeting, American College of Neuropsychopharmacology, Honolulu, Hawaii, December 14, 1993.
21. Wilcox, C.S.; Wesnes, K.A.; Wisselink, P.G.; Simpson, P.M.; Morrissey, J.L. and Happy, J.M. "A Double-Blind, Single-Dose, Four-Way Crossover Comparison of the Effects of Abecarnil, Alprazolam and Placebo in the Evaluation of Cognitive Function in Male Volunteers," 33<sup>rd</sup> Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 13, 1994.
22. Wilcox, C.S. "Alzheimer's Research Update: Midway in the 1990's," Co-sponsored by the Los Angeles Alzheimer's Association and the City of Whittier, Whittier, California, May 4, 1995.
23. Wilcox, C.S.; Cohn, J.B.; Ferguson, J.M.; Dale, J.L. and Fabre, L.F. "A Double-Blind Multicenter Trial of a Low Dose Range and High Dose Range of Gepirone-Extended Release Compared to Placebo in the Treatment of Depressed Outpatients," 35<sup>th</sup> Annual N.C.D.E.U. Meeting, Orlando, Florida, June 1, 1995.
24. Wilcox, C.S.; Katz, B.B.; Morgan, D.L.; Morrissey, J.L. and Schneider, A.L. "Research Patient Recruitment in the 1990's: The Impacts of Managed Care and Increasing Ethnic Diversity," 35<sup>th</sup> Annual N.C.D.E.U. Meeting, Orlando, Florida, June 2, 1995.
25. Wilcox, C.S.; Heiser, J.F.; Morrissey, J.L.; Linden, R.D. and Schneider, A.L. "Identification of the 'Reward Gene' as a Predictor in Studies of Obesity and Smoking Cessation," 34<sup>th</sup> Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 11, 1995.
26. Wilcox, C.S.; Heiser, J.F.; Morrissey, J.L.; Wisselink, P.G. and Herzog, T. "The D<sub>2</sub> Dopamine Receptor and Obesity Drug Trials: the Genetic "Reward" Link," IBC's Second Annual International Symposium on Obesity, Washington, D.C., March 4-6, 1996.
27. Feiger, A.D.; Bielski, R.D.; Bremner, J.; Heiser, J.F.; Trivedi, M. and Wilcox, C.S. "Efficacy of Nefazodone in Continuation Treatment of Depression," 149<sup>th</sup> Annual American Psychiatric Association Meeting, New York City, New York, May 7, 1996.
28. Wilcox, C.S.; Dale, J.L.; Katz, B.B.; Mijares, C.P.; Morgan, D.L.; Morrissey, J.L.; Wassom, N.J. and Heiser, J.F. "An Enhanced Methodology and Study Design for Studies of Smoking Cessation," 20<sup>th</sup> Annual Associates of Clinical Pharmacology Convention, Nashville, Tennessee, May 11-15, 1996.
29. Wilcox, C.S.; Wesnes, K.A.; Heiser, J.F.; Simpson, P.M.; Katz, B.B.; Bianca, R. and Happy, J.M. "A Double-Blind, Eight-Way Crossover Comparison of Abecarnil, Lorazepam and Placebo, Alone and After a Single Dose of Alcohol, on Psychometric Performance in Healthy Volunteers," 36<sup>th</sup> Annual N.C.D.E.U. Meeting, Boca Raton, Florida, May 29, 1996.

30. Feiger, A.D.; Bielski, R.D.; Bremner, J.; Heiser, J.F.; Trivedi, M. and Wilcox, C.S. "Efficacy of Nefazodone in Continuation Treatment of Depression," 36<sup>th</sup> Annual N.C.D.E.U. Meeting, Boca Raton, Florida, May 29, 1996.
31. Feiger, A.D.; Kiev, A.; Shrivastava, R.K.; Wisselink, P.G. and Wilcox, C.S. "Nefazodone versus Sertraline in Outpatients with Major Depression: Focus on Efficacy, Tolerability and Effects on Sexual Function and Satisfaction," 36<sup>th</sup> Annual N.C.D.E.U. Meeting, Boca Raton, Florida, May 30, 1996.
32. Wilcox, C.S.; Heiser, J.F.; Morrissey, J.L.; Katz, B.B.; Linden, R.D. and Schneider, A.L. "A State-of-the-Art Clinical Study Design for Evaluating Potential Treatments of Consumptive Disorders," 32<sup>nd</sup> Annual Drug Information Association Meeting, San Diego, California, June 11, 1996.
33. Wilcox, C.S.; Morrissey, J.L.; Heiser, J.F.; Dale, J.L.; Katz, B.B. and Schneider, A.L. "Recruitment of Migraineurs for Clinical Trials: Insights on Rapid Patient Enrollment *with* Retention," IBC's International Conference on Advances in Treatment and Therapeutic Development in Migraine, Boston, Massachusetts, July 25 & 26, 1996.
34. Wilcox, C.S.; Linden, R.D.; D'Amico, M.F.; Schneider, A.L.; Morrissey, J.L. and Heiser, J.F. "The Tolerability of Nefazodone in the Treatment of Adult and Elderly Patients with Mood Disorders," 35<sup>th</sup> Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 9, 1996.
35. Wilcox, C.S. "Alzheimer's Disease: Research Updates and Caregiving Resources," Invited Speaker - CalTech Senior Care (Staff and Faculty), Connection Lecture Series at California Institute of Technology, Pasadena, California, January 22, 1997.
36. Wilcox, C.S.; Sambunaris, A. and Sachais, B.A. "Strategies for Successful 'Speedy' Collaboration in Clinical Trials," 33<sup>rd</sup> Annual Drug Information Association Meeting, Montréal, Québec, Canada, June 25, 1997.
37. Wilcox, C.S.; Morrissey, J.L.; Heiser, J.F.; Katz, B.B.; Schneider, A.L.; Bacon, P.F. and DeFrancisco, D. "Protocol Design and Predictors of Placebo Response: Studies with Antidepressants and Anxiolytics," 36<sup>th</sup> Annual Meeting, American College of Neuropsychopharmacology, Kamuela, Hawaii, December 10, 1997.
38. Wilcox, C.S.; Linden, R.D.; McQuade, R.; Morrissey, J.L.; D'Amico, M.F.; Schneider, A.L. and Heiser, J.F. "Nefazodone Treatment in Elderly Depressed Patients," 151<sup>st</sup> Annual American Psychiatric Association Meeting, Toronto, Ontario, Canada, June 2, 1998.
39. Wilcox, C.S.; Dren, A.T.; Branconnier, R.J. and Hockley, J.R. "Marketing in Clinical Research - Finding Studies and Patients," 34<sup>th</sup> Annual Drug Information Association Meeting, Boston, Massachusetts, June 8, 1998.

40. Wilcox, C.S.; Linden, R.D.; D'Amico, M.F.; McQuade, R.; Schneider, A.L.; Morrissey, J.L. and Heiser, J.F. "Nefazodone in the Treatment of Elderly Patients with Depression," XXI<sup>st</sup> Collegium Internationale Neuro-Psychopharmacologicum Meeting, Glasgow, Scotland, July 13, 1998.
41. Wilcox, C.S.; Morrissey, J.L.; Heiser J.F.; Katz, B.B.; Cho, F.E.; Grosz, D.E.; Linden, R.D. and DeFrancisco, D.F. "Patients' Motivations as Potential Predictors of Placebo Response: Yesterday and Today," 37<sup>th</sup> Annual Meeting, American College of Neuropsychopharmacology, Las Croabas, Puerto Rico, December 14, 1998.
42. Wilcox, C.S.; Cho, F.E.; Heiser, J.F.; Morrissey, J.L.; Katz, B.B.; Grosz, D.E. and DeFrancisco, D.F. "Placebo Response in Depression Studies: Do Previously Reported Predictors Have Any Utility?" 39<sup>th</sup> Annual N.C.D.E.U. Meeting, Boca Raton, Florida, June 2, 1999.
43. Thase, M.E.; Ferguson, J.M. and Wilcox, C.S. "Citalopram Treatment of Paroxetine Intolerant Patients," 39<sup>th</sup> Annual N.C.D.E.U. Meeting, Boca Raton, Florida, June 3, 1999.
44. Stahl, S.M. and Wilcox, C.S. "Placebo-Controlled Comparison of Citalopram and Sertraline in the Treatment of Anxiety Symptoms in Depressed Patients," 39<sup>th</sup> Annual N.C.D.E.U. Meeting, Boca Raton, Florida, June 3, 1999.
45. Thase, M.E.; Ferguson, J.M. and Wilcox, C.S. "Efficacy and Safety of Citalopram in Paroxetine Intolerant Patients," Annual Meeting of the American Psychiatric Association Institute on Psychiatric Services, New Orleans, Louisiana, November 1, 1999.
46. Wilcox, C.S.; Morrissey, J.L.; Heiser, J.F.; Katz, B.B.; Schneider, A.L.; Delaney, J.E. and Grosz, D.E. "Profiling Migraineurs as Research Subjects: Pharmacoeconomic and Quality of Life Measures," 38<sup>th</sup> Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, Acapulco, Mexico, December 14, 1999.
47. Wilcox, C.S.; Morrissey, J.L.; Heiser, J.F.; Cho, F.E.; Katz, B.B.; Mijares, C.P. and Grosz, D.E. "Major Depressive Disorders and Migraine Headaches: Is Comorbidity a Serious Threat to Homogeneity?" 40<sup>th</sup> Annual N.C.D.E.U. Meeting, Boca Raton, Florida, May 31, 2000.
48. Wilcox, C.S. "Alzheimer's Disease Research Update," invited speaker for City of Norwalk Continuing Education Seminar, Norwalk, California, August 17, 2000.
49. Wilcox, C.S. "Y2K: Medication and Current Research," L.A. Alzheimer's Association and Kiwanis Club of Van Nuys, Van Nuys, California, August 24, 2000.
50. Wilcox, C.S.; Morrissey, J.L.; Cho, F.E.; Heiser, J.F.; Katz, B.B.; Janko, S.E.; Grosz, D.E. and DeFrancisco, D.F. "Profiling Social Anxiety Disorder Research Subjects: An Evaluation of Symptom Severity, Quality of Life and Overall Representativeness," 39<sup>th</sup> Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, San Juan, Puerto Rico, December 11, 2000.

51. Rapaport, M.H.; Londborg, P.; Heiser, J.F.; Wilcox, C.S.; Bartlett, C.L. and Schwartz, G. "Augmentation with Selective NRI Reboxetine Among Partial Responders to SSRI Therapy: Preliminary Report," 41<sup>st</sup> Annual N.C.D.E.U. Meeting, Phoenix, Arizona, May 29, 2001.
52. Wilcox, C.S.; Morrissey, J.L.; Cho, F.E.; Grosz, D.E.; Katz, B.B.; Janko, S.E.; Puppione, A.A. and Heiser, J.F. "The Effects of Gender and Methodology on Homogeneity and Outcomes in Clinical Trials: A Look at Social Anxiety Disorder Research Volunteers," 41<sup>st</sup> Annual N.C.D.E.U. Meeting, Phoenix, Arizona, May 30, 2001.
53. Grosz, D.E.; Morrissey, J.L. and Wilcox, C.S. "Almotriptan is Effective for Multiple Migraine Attacks," 10<sup>th</sup> International Headache Congress, New York, New York, June 30, 2001.
54. Thase, M.E. and Wilcox, C.S. "The Efficacy of Citalopram in the Treatment of Patients Who Failed Treatment with Fluoxetine or Paroxetine," accepted for presentation at the 14<sup>th</sup> European College of Neuropsychopharmacology (E.C.N.P.) Congress, Istanbul, Turkey, October 13-17, 2001.
55. Wilcox, C.S.; Heiser, J.F.; Morrissey, J.L.; Grosz, D.E.; Cho, F.E.; Katz, B.B.; Janko, S.E. and Linden, R.D. "Protocol Design and Predictors of Placebo Response in Anxiety Disorders: Generalized Anxiety Disorder vs. Social Anxiety Disorder," 40<sup>th</sup> Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, Waikoloa, Hawaii, December 10, 2001.
56. Wilcox, C.S.; Heiser, J.F.; Rapaport, M.H.; Londborg, P.D. and Schwartz, G.E. "Reboxetine Augmentation of Fluoxetine for Patients with Major Depressive Disorder: An 8-Week Open-Label Study," 42<sup>nd</sup> Annual NCDEU Meeting, Boca Raton, Florida, June 11, 2002.
57. Wilcox, C.S.; Heiser, J.F.; Rapaport, M.H.; Londborg, P. and Schwartz, G. "Reboxetine Augmentation of Fluoxetine for Patients with Major Depressive Disorder: An 8-Week Open-Label Study," European College of Neuropsychopharmacology (E.C.N.P.) Congress, Barcelona, Spain, October 6, 2002.
58. Wilcox, C.S.; Morrissey, J.L.; Heiser, J.F.; Cho, F.E.; Grosz, D.E.; Katz, B.B. and DeFrancisco, D.F. "Venlafaxine-ER vs. Placebo in Adults with Generalized Social Anxiety Disorder," 41<sup>st</sup> Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, San Juan, Puerto Rico, December 11, 2002.
59. Wilcox, C.S.; Morrissey, J.L.; Cho, F.E.; Heiser, J.F.; Katz, B.B.; Grosz, D.E.; Tong, M. and DeFrancisco, D. "Placebo Response and Social Anxiety Disorder: 'What Happened to Reliable Predictors?'," 43<sup>rd</sup> Annual NCDEU Meeting, Boca Raton, Florida, May 28, 2003.
60. Wilcox, C.S.; Katz, B.B.; Heiser, J.F.; Cho, F.E.; Morrissey, J.L.; Grosz, D.E.; Hardy, A.I. and DeFrancisco, D.F. "Placebo Response and Anxiety Disorders: A Critical Evaluation of Influential Variables," 16<sup>th</sup> European College of Neuropsychopharmacology (E.C.N.P.) Congress, Prague, Czech Republic, September 23, 2003.

61. Wilcox, C.S.; Katz, B.B.; Heiser, J.F.; Hardy, A.I.; Cho, F.E.; Adkins, D.M.; Morrissey, J.L. and Grosz, D.E. "Profiling Smoking Cessation Research Subjects: Demographic and Baseline Characteristics as Predictors of Retention/Completion," 42<sup>nd</sup> Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, San Juan, Puerto Rico, December 9, 2003.
62. Wilcox, C.S.; Morrissey, J.L.; Hardy, A.I.; Heiser, J.F.; Katz, B.B.; Adkins, D.M.; Tong, M. and Grosz, D.E. "Predictors of Success in Smoking Cessation Studies: An Analysis of Socioeconomic, Behavioral and Demographic Variables," 43<sup>rd</sup> Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, San Juan, Puerto Rico, December 15, 2004.
63. Wilcox, C.S.; Heiser, J.F.; Katz, B.B.; Thach, A.L.; Henry, M.M.; Cooper, M.E.; Oskooilar, N.; Morrissey, J.L. and Grosz, D.E. "Behavioral, Demographic and Socioeconomic Variables as Potential Predictors of Successful Smoking Cessation, Vis-à-Vis a Clinical Trial," 11<sup>th</sup> Annual Society for Research on Nicotine and Tobacco (S.R.N.T.) Meeting [and Joint 7<sup>th</sup> Annual SRNT European Conference], Prague, The Czech Republic, March 21, 2005.
64. Wilcox, C.S.; Oskooilar, N.; Katz, B.B.; Grosz, D.E.; Morrissey, J.L.; Henry, M.M. and De Francisco, D.F. "Pharmacogenomics from the Atypical Depression Study Participants' Perspective," 46<sup>th</sup> Annual NCDEU Meeting, Boca Raton, Florida, June 14, 2006.
65. Wilcox, C.S.; Heiser, J.F.; Katz, B.B.; Oskooilar, N.; Henry, M.M.; Grosz, D.E.; Morrissey, J.L.; Noble, E.P. and De Francisco, D.F. "A Double-Blind Study Comparing Varenicline with Bupropion-SR and Placebo for Smoking Cessation: Results from a Single Center," 45<sup>th</sup> Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, Hollywood, Florida, December 4, 2006.
66. Wilcox, C.S.; Morrissey, J.L.; Grosz, D.E.; Heiser, J.F.; Henry, M.M.; Oskooilar, N.; Katz, B.B. and De Francisco, D.F. "Are Adult Attention-Deficit Hyperactivity Disorder Research Subjects Representative of the Adult Attention-Deficit Hyperactivity Disorder Population at Large?" 46<sup>th</sup> Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, Boca Raton, Florida, December 10, 2007.
67. Wilcox, C.S.; Oskooilar, N.; Tong, M.; Grosz, D.E.; Morrissey, J.L.; Katz, B.B.; Henry, M.M. and De Francisco, D.F. "Do Depressed Obese Research Patients Respond Differently to Antidepressant Treatment When Compared with Non-Obese Depressed Patients?" 48<sup>th</sup> Annual NCDEU Meeting, Phoenix, Arizona, May 29, 2008.
68. Wilcox, C.S.; Oskooilar, N.; Katz, B.B.; Henry, M.M.; Tong, M.; Grosz, D.E.; Morrissey, J.L. and De Francisco, D.F. "A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Vilazodone in Patients with Major Depressive Disorder: Results from a Single Center" 47<sup>th</sup> Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, Scottsdale, Arizona, December 10, 2008.

69. Dunayevich, E.; Erickson, J.; Oskooilar, N.; Billes, S.J. and Wilcox, C.S. "Naltrexone SR/Bupropion SR Combination for Smoking Cessation and Prevention of Associated Weight Gain in Overweight and Obese Subjects," 162<sup>nd</sup> Annual American Psychiatric Association Meeting, San Francisco, California, May 20, 2009.
70. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Henry, M.M.; Grosz, D.E.; Katz, B.B. and De Francisco, D.F. "Transforming Patient Recruitment and Retention Strategies for CNS Clinical Trials: Today's Patient Perspective on the Transactional Model," 49<sup>th</sup> Annual NCDEU Meeting, Hollywood, Florida, July 1, 2009.
71. Wilcox, C.S.; Noble, E.P.; Ritchie, T.; Oskooilar, N.; Katz, B.B.; Grosz, D.E.; Henry, M.M.; Morrissey, J.L. and De Francisco, D.F. "Integrating Pharmacogenomics in Drug Development: A Preliminary Report on a Study of the Molecular Genetic (DRD2) Basis of Nicotine Addiction and Treatment Response in Cigarette Smokers," 48<sup>th</sup> Annual American College of Neuropsychopharmacology (A.C.N.P.) Meeting, Hollywood, Florida, December 9, 2009.
72. Wilcox, C.S.; Noble, E.P.; Oskooilar, N.; Henry, M.M.; Ritchie, T. L.; Grosz, D.E.; Katz, B.B. and Heiser, J.F. "Biomarkers and Expediting Drug Development: An Interim Report on the Molecular Genetic (DRD2) Basis of Nicotine Addiction and Treatment Response," 50<sup>th</sup> Annual NCDEU Meeting, Boca Raton, Florida, June 16, 2010.
73. Harris-Collazo, R.; Wilcox, C.; Erickson, J., Billes, S.K.; Kim, D. and Dunayevich, E. "An Open-Label Study of Naltrexone SR/Bupropion SR Combination Therapy for Smoking Cessation in Overweight and Obese Subjects," 11<sup>th</sup> International Congress on Obesity, Stockholm, Sweden, July 11-15, 2010.
74. Wilcox, C.S.; Oskooilar, N.; Katz, B.B.; Grosz, D.E.; Tong, M.; Morrissey, J.L.; Henry, M.M. and De Francisco, D.F. "A Randomized, Double-Blind, Placebo-Controlled, Pooled Data Single-Site Assessment of the Efficacy and Safety of Vilazodone in Patients with Major Depressive Disorder," 51<sup>st</sup> Annual NCDEU Meeting, Boca Raton, Florida, June 15, 2011.
75. Wilcox, C.S. "Protocol Complexity at the Site Level: From the Sites' Perspective," CNS Summit Annual Meeting, Boca Raton, Florida, November 18, 2011.
76. Wilcox, C.S.; Oskooilar, N.; Tong, M.; Morrissey, J.L.; De Francisco, D.F.; Henry, M.M. and Grosz, D.E. "Do Current Internet-Based Patient Recruitment Methods Impact Patient Retention and Completion Rates in Depression Studies and Are These Metrics Truly Indicative of Positive Outcomes?" 50<sup>th</sup> Annual ACNP Meeting, Waikoloa Beach, Hawaii, December 7, 2011.
77. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Grosz, D.E.; Henry, M.M.; Guevarra, K.A. and De Francisco, D.F. "The Impact(s) of Family Psychiatric History on Signal Detection and Placebo-Response: Meta-Analysis," 52<sup>nd</sup> Annual NCDEU Meeting, Phoenix, Arizona, May 31, 2012.

78. Wilcox, C.S.; Oskooilar, N.; Tong, M.; Morrissey, J.L.; Henry, M.M.; Grosz, D.E. and De Francisco, D.F. “Statistical Analyses in Smoking Cessation Clinical Trials: A Simplified Model Encompassing More Complexity,” 14th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT) Europe, Helsinki, Finland, August 31, 2012.
79. Shiovitz, T.M.; Wilcox, C.S.; Gevorgyan, L.; Morrissey, J.L.; Zarrow, M.E. and Shawkat, M.A. “CNS Sites Cooperate to Detect Duplicate Subjects with a Clinical Trial Subject Registry,” 3<sup>rd</sup> Annual CNS Summit Meeting, Boca Raton, Florida, November 16, 2012.
80. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Henry, M.M.; Grosz, D.E. and Tong, M. “The Failed CNS Studies Phenomenon: Is the Final Factor Looking Us Right in the Eye?” 51<sup>st</sup> Annual ACNP Meeting, Hollywood, Florida, December 5, 2012.
81. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Grosz, D.E.; Litzinger, J.D.; Henry, M.M.; Feldman, C.R. and De Francisco, D.F. “Research Fraud and Failed Clinical Trials via Fictitious Study Participants: Is it an American or an International Problem?” 25<sup>th</sup> Annual Drug Information Association (DIA) EuroMeeting, Amsterdam, Netherlands, March 3-6, 2013.
82. Shiovitz, T.M.; Manlosa, N.B.; Gevorgyan, L.; Zarrow, M.E. and Wilcox, C.S. “Characteristics of Duplicate Subjects in a Clinical Trial Subject Registry,” 53<sup>rd</sup> Annual NCDEU Meeting, Hollywood, Florida, May 29, 2013.
83. Shiovitz, T.M.; Wilcox, C.S.; Gevorgyan, L.; Mehra, V. and Mangano, T.C. “Using a Subject Registry to Create a Duplicate-Free Corridor for Conducting Clinical Trials,” CNS Summit Conference, Boca Raton, Florida, November 15, 2013.
84. Wilcox, C.S. – Panelist. “Stakeholder Collaboration at the Site Level: Improving Clinical Trial Success,” CNS Summit Conference, Boca Raton, Florida, November 16, 2013.
85. Wilcox, C.S.; Morrissey, J.L.; Oskooilar, N.; Henry, M.M.; Grosz, D.E.; Tong, M. and De Francisco, D.F. “Protocol Complexity and Enrollment Eligibility Exclusivity: Are Today’s Depression Study Volunteers Truly Representative?” 52<sup>nd</sup> Annual ACNP Meeting, Hollywood, Florida, December 10, 2013.
86. Wilcox, C.S. and Lucariello, V.M. “Hidden Costs for Sites and Sponsors: What costs are not in study budgets but not ‘the cost of doing business?’” MAGI’s Clinical Research Conference – 2014 East, Philadelphia, Pennsylvania, May 5, 2014.
87. Romano, S.; Jovic, S.; Burch, D. and Wilcox, C.S. “Real Time: CNS Edition – A Candid and Interactive Session,” moderated by Amir Kalali, M.D. – 5<sup>th</sup> Annual CNS Summit Conference, Boca Raton, Florida, November 15, 2014.
88. Wilcox, C.S.; Oskooilar, N.; Guevarra, K.A.; Tong, M.; Morrissey, J.L.; Grosz, D.E. and De Francisco, D.F. “Preliminary Report: Does a ‘Reduce-to-Quit’ Smoking Cessation Strategy Increase or Decrease Success?” 15<sup>th</sup> Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT) Europe, Santiago de Compostela – Galicia, Spain, September 20, 2014.



89. Wilcox, C.S.; Oskooilar, N.; Guevarra, K.A.; Tong, M.; Morrissey, J.L.; Grosz, D.E. and De Francisco, D.F. "Smoking Cessation Through Reduction: Does It Enhance Or Diminish Successful Quitting?" 53rd Annual ACNP Meeting, Phoenix, Arizona, December 9, 2014.
90. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Tong, M.; Grosz, D.E.; Guevarra, K.A.; Feldman, C.R. and De Francisco, D.F. "The Efficacy of Varenicline Compared to Placebo for Smoking Cessation Using a Reduce-to-Quit Strategy: One Research Center's Results" 21<sup>st</sup> Annual SRNT Meeting, Philadelphia, Pennsylvania, February 26, 2015.
91. Wilcox, C.S.; Oskooilar, N.; Guevarra, K.A.; Tong, M.; Grosz, D.E.; Morrissey, J.L.; Henry, M.M. and De Francisco, D.F. "A Double-Blind, Active- and Placebo-Controlled Evaluation of the Neuropsychiatric Safety and Efficacy of Varenicline and Bupropion for Smoking Cessation in Subjects with (Pre-Existing) Psychiatric Disorders: An Objective Blinded Analysis" 54<sup>th</sup> Annual ACNP Meeting, Hollywood, Florida, December 7, 2015.
92. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; De Francisco, D.F.; Guevarra, K.A.; Grosz, D.E.; Henry, M.M.; Litzinger, J.D. and Tong, M. "Smoking Cessation in Patients with a Prior or Current Psychiatric Disorder: A Double-Blind Comparative Analysis of the Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, Nicotine Replacement Therapy [NRT] and Placebo" 22<sup>nd</sup> Annual Meeting of the Society for Research on Nicotine and Tobacco, Chicago, Illinois, March 3, 2016.
93. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Rosenberg, D.; Tong, M.; Henry, M.; Badgett, L. and Grosz, D. "Could a Paradigm Shift in Consumptive Disorders Research Benefit Patients and Sponsors Alike? A Smoking Cessation Case Study Reinforces → The Manner in Which We Look at Things, Determines What We See!" CNS Summit 2016, Boca Raton, Florida, October 28, 2016.
94. Wilcox, C.S.; Tong, M.; Oskooilar, N.; Morrissey, J.L.; De Francisco, D.; Henry, M.; Badgett, L. and Grosz, D. "A 12-Week, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Phase-2, Dose Selection Study of Lorcaserin Hydrochloride for Smoking Cessation: Preliminary Report," 55<sup>th</sup> Annual ACNP Meeting, Hollywood, Florida, December 7, 2016.
95. Wilcox, C.S.; Oskooilar, N.; Tong, M.; Grosz, D.; Henry, M.; Morrissey, J.; Washington, J. and De Francisco, D. "A Double-Blind, Randomized, Placebo-Controlled, Phase-2, Dose Selection Study of Lorcaserin Hydrochloride for Smoking Cessation: Different Analyses Produce Markedly Different Results," Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting, Florence, Italy, March 9, 2017.
96. Wilcox, C.S.; Grosz, D.E.; Tong, M.; Rosenberg, D.A.; Morrissey, J.L.; De Francisco, D.F.; Feldman, C.R.; Henry, M.M.; Badgett, L.M. and Oskooilar, N. "Serving the Needs of Our Increasingly Diverse Population: It All Begins with Recruitment!" ASCP Annual Meeting, Miami Beach, Florida, June 1, 2017.

97. Harrison, J.; Wilcox, C.; Carrillo, M.; Pendergrass, C.; Gold, M. and Holt, B. Panel Session: “Revolutionizing Outcome Measures in Alzheimer’s Trials” CNS Summit 2017, Boca Raton, Florida, November 17, 2017.
98. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Rosenberg, D.A.; Tong, M.; Henry, M.M. and Grosz, D.E. “Successful Lifespan-Targeted Patient Recruitment Strategies for Outpatient Psychiatric and Neurological Clinical Trials,” ASCP Annual Meeting, Miami, Florida, May 30, 2018.
99. Malhotra, S.; Wise-Rankovic, A.; Wilcox, C.S.; Metcalfe, J.; Mitsi, G.; Boyer, S.; Webster, I. and Grom, T. “Women in Leadership: Enhancing Success and Culture Life Series,” 9<sup>th</sup> Annual CNS Summit Conference, Boca Raton, Florida, November 1, 2018.
100. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Rosenberg, D.A.; Tong, M.; Henry, M.M. and Grosz, D.E. “Innovations in Personalized Medicine: A Pilot Study Looking at the Potential vs. the Promise in Major Depressive Disorder,” ASCP Annual Meeting, Scottsdale, Arizona, May 29, 2019.
101. Wilcox, C.S.; Verghese, C.; Simmons, A. and Franceschi, L.M.K. “Layperson/Plain Language Summaries: Can Sponsors, CROs and Sites Deliver by 2020?” 10<sup>th</sup> Annual CNS Summit Conference, Boca Raton, Florida, November 1, 2019.
102. Wilcox, C.S. “Public Image and Sentiment Toward the Pharmaceutical Industry: What Can We Do to Reverse the Negative Trend? ASCP Annual Meeting, Virtual Conference, May 29, 2020.
103. Wilcox, C.S. “Alzheimer’s #115: A Global 3-D Perspective for Patients, Caregivers, Clinical Researchers, Clinicians and Concerned Citizens,” 34<sup>th</sup> Annual ECNP Congress, Lisbon, Portugal, October 4, 2021.
104. Malhotra, S.; Wise, A.; Wilcox, C.; Versavel, S.; Whitmore, S. and Mitchell, Z. “Achieving Diversity in Clinical Trials: Overcoming Industry Challenges to Develop Actionable Plans for Implementation,” Spotlight Session Panel Presentation and Discussion, 12<sup>th</sup> Annual CNS Summit Conference, Boston, Massachusetts, November 8, 2021.
105. Wilcox, C.S. “Diversity, Equity and Inclusion: Alzheimer’s and Dementia Research-Related Global Challenges, Solutions and Opportunities,” 12<sup>th</sup> Annual CNS Summit Conference, Boston, Massachusetts, November 9, 2021.
106. Malhotra, S.; Wise, A.; Wilcox, C. and Versavel, S. “Achieving Diversity in Clinical Trials,” Panel Session, ASCP Annual Meeting, Scottsdale, Arizona, June 2, 2022.
107. Wilcox, C. “Diversity, Equity and Inclusion: Globalized Insights for Localized Strategies,” ASCP Annual Meeting, Scottsdale, Arizona, June 2, 2022.

SELECTED SPECIALIZED TRAINING

- 11/08/91 “Alzheimer’s Disease Assessment Scale” (ADAS)  
Training Session, Richard Mohs, Ph.D. ~ Instructor  
La Jolla, California
- 12/01-02/94 “Alzheimer’s Disease Assessment Scale” (ADAS)  
Training Session, Richard Mohs, Ph.D. ~ Instructor  
Palm Beach, Florida
- 12/01-02/94 “CIBIC-Plus Semi-Structured Clinical Interview”  
Training Session, Drs. Ferris and Reisberg,  
Palm Beach, Florida
- 06/14/96 “Alzheimer’s Disease Functional Assessment and Change Scale” (ADFACS)  
Training Session, Richard Mohs, Ph.D. ~ Instructor  
Coronado Bay, California
- 01/31/97 “Structured Clinical Interview for DSM-IV Axis I Disorders,” Training Session,  
Michael B. First, M.D. (Columbia University)  
New Orleans, Louisiana
- 01/31/97 “SIGH-D, The Structured Interview for the Hamilton Depression Rating Scale,”  
Training Session, Janet B. W. Williams, D.S.W. (Columbia University)  
New Orleans, Louisiana
- 02/26/98 “Structured Clinical Interview Training for DSM-IV-An Update”  
Michael B. First, M.D. (Columbia University)  
Atlanta, Georgia
- 02/26/98 “Hamilton Depression Scale Anchor Points and Conventions: Live Patient  
Interviews,” John P. Feighner, M.D. ~ Instructor  
Atlanta, Georgia
- 04/13/98 “The Clinical Dementia Rating (Worksheet)”: CDR Administration of a semi-  
structured informant + patient clinical interview. Dr. John Morris  
Dallas, Texas
- 04/10/99 “The Alzheimer’s Disease Assessment Scale (ADAS-Cog): Administration and  
Scoring for the 1994 Revised Edition,” Richard C. Mohs, Ph.D.  
Beverly Hills, California
- 06/05/99 “Structured Clinical Interview for DSM-IV Axis I Disorders, Modifications for  
Clinical Trials,” Training Session, Michael B. First, M.D. (Columbia University)  
Palm Beach, Florida

- 06/05/99 “Liebowitz Social Anxiety Scale (LSAS),” Michael Liebowitz, M.D.  
(New York State Psychiatric Institute)  
Palm Beach, Florida
- 10/07/99 “Liebowitz Social Anxiety Scale (LSAS),” Nicholas DeMartinis, M.D.  
(University of Pennsylvania)  
Phoenix, Arizona
- 10/07/99 “Modified MINI International Neuropsychiatric Interview (MINI),” Juris Janavs, M.D.  
(University of South Florida, College of Medicine)  
Phoenix, Arizona
- 04/18/00 “Combined Structured Interview for the HAM-D<sub>21</sub> and MADRS,” Michael B. First,  
M.D. (Columbia University)  
Oak Brook Hills, Illinois
- 06/16/00 “The Hamilton Anxiety Scale: Inter-Rater Reliability Training,” Stephen Stahl, M.D.,  
Ph.D. (University of California, San Diego)  
San Diego, California
- 04/20/01 “Review of the CIBIC - Plus Scale,” Jacobo Mintzer, M.D.  
(Alzheimer’s Research & Clinical Programs - Charleston, North Carolina)  
Miami, Florida
- 10/20/01 “Modified MINI International Neuropsychiatric Interview (MINI),” Juris Janavs, M.D.  
(University of South Florida, College of Medicine)  
Toronto, Canada
- 10/23/01 “Modified MINI International Neuropsychiatric Interview (MINI),” Juris Janavs, M.D.  
(University of South Florida, College of Medicine)  
Amelia Island, Florida
- 05/01/02 “Alzheimer’s Disease Assessment Scale (ADAS-Cog),” Richard C. Mohs, Ph.D.  
(Professor of Psychiatry, Department of Psychiatry, Mount Sinai School of Medicine)  
Phoenix, Arizona
- 05/01/02 “Review of CIBIC-Plus/ADCS-CGIC, Clinician’s Interview-Based Impression of  
Change,” Frederick A. Schmitt, Ph.D. (Associate Professor of Neurology, Department  
of Psychiatry, University of Kentucky)  
Phoenix, Arizona
- 02/05/03 “Assessment of the Severely Demented Patient: *The Severe Impairment Battery*,”  
Judith Saxton, Ph.D. (Associate Professor of Psychiatry, University of Pittsburgh)  
Miami, Florida
- 02/05/03 “Clinician’s Impression of Change: Review of *CIBIC-Plus*,” Frederick A. Schmitt,  
Ph.D. (Professor of Neurology, University of Kentucky ADRC)  
Miami, Florida

- 06/07/04 “The Science of Successful Rating (HAMD, MADRS),” Alan D. Feiger, M.D.,  
Research Training Associates  
Washington, D.C.
- 04/08/05 “Modified MINI International Neuropsychiatric Interview (MINI), Version 5.0.0,”  
Juris Janavs, M.D., M.B.A. (University of South Florida, College of Medicine)  
Phoenix, Arizona
- 04/09/05 “Attention-Deficit Hyperactivity Disorder – Rating Scale (ADHD-RS),” Lenard Adler,  
M.D. (New York University School of Medicine)  
Chicago, Illinois
- 01/28/06 “Neuropsychological Test Battery (NTB): WMS-R (ViPA), WMS-R (VePA), WMS-R  
Digit Span (DS), Rey Auditory Verbal Learning Test (RAVLT), Controlled Word  
Association Test (COWAT) and Category Fluency Test (CFT),” Dr. John Harrison,  
Miami, Florida
- “Clinical Dementia Rating – Sum of Boxes (CDR-SOB); Alzheimer’s Disease  
Cooperative Study Clinical Global Impression of Change (ADCS – CGIC); Disability  
Assessment for Dementia (DAD),” Amy Veroff, Ph.D.  
Miami, Florida
- “Clinical Dementia Rating – Sum of Boxes (CDR-SOB),” Dr. Stacy Schneider  
(ADRC – Washington University, St. Louis, Missouri)  
Miami, Florida
- 05/04/07 “Columbia Suicide – Severity Rating Scale (C-SSRS),” Andres Digenio, M.D., Ph.D.  
and Alan Krasner, M.D. (Pfizer Research & Development)  
Phoenix, Arizona
- 02/20/08 “Neuropsychological Test Battery (NTB): WMS-R (ViPA), WMS-R (VePA),  
RAVLT, WMS-R Digit Span, COWAT, CFT,” Lisle R. Kingery, Ph.D. (i3 Clinical  
Training and Assessments)  
Baltimore, Maryland
- 02/20/08 “Disability Assessment for Dementia (DAD) and Neuropsychiatric Inventory (NPI),”  
Amy Veroff, Ph.D. (i3 Clinical Training and Assessments)  
Baltimore, Maryland
- 02/21/08 “Mini Mental State Exam (MMSE), Alzheimer’s Disease Assessment Scale (ADAS-  
Cog), Clinical Dementia Rating – Sum of Boxes (CDR-SOB), Blessed Functional  
Activity Scale – Short Form (BFAS-SF),” Amy Veroff, Ph.D.  
Baltimore, Maryland
- 03/05/08 “Adult ADHD Investigator Symptom Rating Scale (AISRS),” Lenard A. Adler, M.D.  
(Associate Professor of Psychiatry and Neurology, New York University School of  
Medicine)  
Philadelphia, Pennsylvania

- 03/07/08 “Columbia-Suicide Severity Rating Scale (C-SSRS),” Kelly Posner, Ph.D., Principal Investigator, Suicidality Classification Center, Assistant Professor, Columbia University, via Webinar
- 04/10/08 “Columbia-Suicide Severity Rating Scale (C-SSRS),” Kelly Posner, Ph.D., New York State Psychiatric Institute, Assistant Professor, Columbia University  
Miami, Florida
- 09/25/08 “Columbia-Suicide Severity Rating Scale (C-SSRS),” Kelly Posner, Ph.D., Principal Investigator, Suicidality Classification Center, Assistant Professor, Columbia University  
Dallas, Texas
- 02/26/09 “Overall Assessment of the Speaker’s Experience of Stuttering (OASES) Scale,” J. Scott Yaruss, Ph.D., CCC-SLP, Associate Professor, Communication Science and Disorders, University of Pittsburgh and Co-Director, Stuttering Center of Western Pennsylvania  
Amelia Island, Florida
- 10/22/09 “Columbia-Suicide Severity Rating Scale (C-SSRS),” Kelly Posner, Ph.D., Principal Investigator, Suicidality Classification Center, Assistant Professor, Columbia University  
Chicago, Illinois
- 03/03/10 “Columbia – Suicide Severity Rating Scale (C-SSRS),” Kelly Posner, Ph.D., Principal Investigator, Suicidality Classification Center, Assistant Professor, Columbia University  
Jersey City, New Jersey
- 03/22/10 Behavior Rating Inventory of Executive Function – Adult Version (BEHAVE-A©), Robert M. Roth, Ph.D., Assistant Professor of Psychiatry, Neuropsychology Program, Dartmouth Medical School  
WebEx
- 06/07/11 “The Montgomery-Asberg Depression Rating Scale (MADRS),” review, interpretation and administration. Stuart Montgomery, M.D. (Imperial College, London, England)  
Jersey City, New Jersey
- 09/27/13 “ADHD Advances: Challenges and Opportunities,” MediCom Worldwide, Inc.  
Washington, D.C.
- 03/20/14 Motivational Interviewing for Enhanced Compliance →Retention→in Smoking Cessation. Nader Oskooilar, M.D., Ph.D.  
Cypress, California